Terms: = Uterine cancer AND MSH2, COCA1, 4436, ENSG00000095002, HNPCC, FCC1, HNPCC1, P43246 AND Treatment
61 results:
1. Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer.
D'Agostino E; Mastrodomenico L; Ponzoni O; Baldessari C; Piombino C; Pipitone S; Giuseppa Vitale M; Sabbatini R; Dominici M; Toss A
Cancer Treat Rev; 2024 May; 126():102723. PubMed ID: 38555857
[TBL] [Abstract] [Full Text] [Related]
2. γδ T cell-mediated cytotoxicity against patient-derived healthy and cancer cervical organoids.
Dong J; Holthaus D; Peters C; Koster S; Ehsani M; Quevedo-Olmos A; Berger H; Zarobkiewicz M; Mangler M; Gurumurthy RK; Hedemann N; Chumduri C; Kabelitz D; Meyer TF
Front Immunol; 2023; 14():1281646. PubMed ID: 38090581
[TBL] [Abstract] [Full Text] [Related]
3. Metastasis of endometrial adenocarcinoma masquerading as a primary rectal cancer: A rare case report with literature review.
Li M; Zheng W
Medicine (Baltimore); 2023 Nov; 102(46):e36170. PubMed ID: 37986305
[TBL] [Abstract] [Full Text] [Related]
4. Applicability of the FDA-approved Immunohistochemical Panel for Identification of MMRd Phenotype in uterine Endometrioid Carcinoma.
Adachi S; Kimata JI; Hanami K; Adachi K; Igarashi T; Liang SG; Ishida Y; Fujino T; Yamazaki K
Appl Immunohistochem Mol Morphol; 2024 Jan; 32(1):24-31. PubMed ID: 37859432
[TBL] [Abstract] [Full Text] [Related]
5. A retrospective study of consistency between immunohistochemistry and polymerase chain reaction of microsatellite instability in endometrial cancer.
Wang C; Kuang W; Zeng J; Ren Y; Liu Q; Sun H; Feng M; Liang D
PeerJ; 2023; 11():e15920. PubMed ID: 37663290
[TBL] [Abstract] [Full Text] [Related]
6. Comparison of PD-L1 expression and MMR status between primary and matched metastatic lesions in patients with cervical cancer.
Liu H; Sun L; Lian J; Wang L; Xi Y; Zhao G; Wang J; Lan X; Du H; Yan W; Bu P; Wang P; Moore A; Zhao H
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11397-11410. PubMed ID: 37378674
[TBL] [Abstract] [Full Text] [Related]
7. Germline drivers of gynecologic carcinosarcomas.
Sia TY; Gordhandas SB; Birsoy O; Kemel Y; Maio A; Salo-Mullen E; Sheehan M; Hensley ML; Rubinstein M; Makker V; Grisham RN; O'Cearbhaill RE; Roche KL; Mueller JJ; Leitao MM; Sonoda Y; Chi DS; Abu-Rustum NR; Berger MF; Ellenson LH; Latham A; Stadler Z; Offit K; Aghajanian C; Weigelt B; Mandelker D; Liu YL
Gynecol Oncol; 2023 Jul; 174():34-41. PubMed ID: 37149903
[TBL] [Abstract] [Full Text] [Related]
8. The expression of programmed death-ligand 1 and programmed death-ligand 2 in endometrial carcinosarcoma: Correlation with mismatch repair protein expression status, tumor-infiltrating lymphocyte infiltration, and clinical outcomes.
Atılgan AO; Tepeoğlu M; Özen Ö; Reyhan ANH; Ayhan A
Ann Diagn Pathol; 2023 Aug; 65():152137. PubMed ID: 37060883
[TBL] [Abstract] [Full Text] [Related]
9. Clinical characteristics and prognostic characterization of endometrial carcinoma: a comparative analysis of molecular typing protocols.
Yang Z; Yang X; Liu X; Ma K; Meng YT; Yin HF; Wen J; Yang JH; Zhen Z; Feng ZH; Liao QP
BMC Cancer; 2023 Mar; 23(1):243. PubMed ID: 36918828
[TBL] [Abstract] [Full Text] [Related]
10. Comparison of Tissue Mismatch Repair Protein Deficiency between Early- and Advanced-Stage Endometrial cancer.
Chaowiwatkun K; Trongwongsa T; Rodpenpear N; Nutthachote P
Asian Pac J Cancer Prev; 2023 Jan; 24(1):345-351. PubMed ID: 36708586
[TBL] [Abstract] [Full Text] [Related]
11. Application of molecular classification to guiding fertility-sparing therapy for patients with endometrial cancer or endometrial intraepithelial neoplasia.
Zhang X; Chen D; Zhao X; Wang C; He Y; Chen Y; Wang J; Shen D
Pathol Res Pract; 2023 Jan; 241():154278. PubMed ID: 36580798
[TBL] [Abstract] [Full Text] [Related]
12. Histopathological and molecular findings in 98 cases of endometrial carcinoma: MMR, p53 and next generation sequencing.
Karabağ S; Şentürk M; Söğüt FC; Ergül ÖS; Ersoy T
Pathol Res Pract; 2023 Jan; 241():154275. PubMed ID: 36528987
[TBL] [Abstract] [Full Text] [Related]
13. The statuses of HER2 expression and mismatch repair in endometrial clear cell carcinoma.
Bayramoglu Z; Erozbek SY; Ozdemir IA; Ulker V; Muezzinoglu B
Pathol Res Pract; 2023 Jan; 241():154258. PubMed ID: 36516643
[TBL] [Abstract] [Full Text] [Related]
14. CircWDR26 regulates endometrial carcinoma progression via miR-212-3p-mediated typing genes msh2.
Lei TX; He DJ; Cao J; Lv WG
Eur J Med Res; 2022 Jul; 27(1):135. PubMed ID: 35897048
[TBL] [Abstract] [Full Text] [Related]
15. Utility of germline multi-gene panel testing in patients with endometrial cancer.
Karpel HC; Chern JY; Smith J M; Smith A J; Pothuri B
Gynecol Oncol; 2022 Jun; 165(3):546-551. PubMed ID: 35483985
[TBL] [Abstract] [Full Text] [Related]
16. The clinical features and management of Lynch syndrome-associated ovarian cancer.
Ran X; Jing H; Li Z
J Obstet Gynaecol Res; 2022 Jul; 48(7):1538-1545. PubMed ID: 35478369
[TBL] [Abstract] [Full Text] [Related]
17. Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of Response to Immune Checkpoint Inhibitors in Gynecologic cancers.
Noh JJ; Kim MK; Choi MC; Lee JW; Park H; Jung SG; Joo WD; Song SH; Lee C
Cancer Res Treat; 2022 Oct; 54(4):1200-1208. PubMed ID: 34902958
[TBL] [Abstract] [Full Text] [Related]
18.
Kaneko E; Sato N; Sugawara T; Noto A; Takahashi K; Makino K; Terada Y
J Gynecol Oncol; 2021 Nov; 32(6):e79. PubMed ID: 34431253
[TBL] [Abstract] [Full Text] [Related]
19. Endometrial cancer in Lynch syndrome.
Zhao S; Chen L; Zang Y; Liu W; Liu S; Teng F; Xue F; Wang Y
Int J Cancer; 2022 Jan; 150(1):7-17. PubMed ID: 34398969
[TBL] [Abstract] [Full Text] [Related]
20. PD-L1 expression and immune stromal features in HPV-independent cervical adenocarcinoma.
Song F; Jia M; Yu S; Cao L; Sun PL; Gao H
Histopathology; 2021 Nov; 79(5):861-871. PubMed ID: 34156708
[TBL] [Abstract] [Full Text] [Related]
[Next]
